Search details
1.
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Breast Cancer Res
; 26(1): 69, 2024 Apr 22.
Article
in English
| MEDLINE | ID: mdl-38650031
2.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Article
in English
| MEDLINE | ID: mdl-34081848
3.
Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.
Br J Cancer
; 128(6): 1030-1039, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36604587
4.
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Breast Cancer Res Treat
; 199(2): 243-252, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36944848
5.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med
; 380(7): 617-628, 2019 02 14.
Article
in English
| MEDLINE | ID: mdl-30516102
6.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Breast Cancer Res Treat
; 192(1): 153-161, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-35112166
7.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 555-564, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35230585
8.
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 22(1): 9, 2020 Jan 22.
Article
in English
| MEDLINE | ID: mdl-31969184
9.
What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report.
Cancer
; 126(23): 5022-5029, 2020 12 01.
Article
in English
| MEDLINE | ID: mdl-32970346
10.
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
Cancer
; 126(13): 3132-3139, 2020 07 01.
Article
in English
| MEDLINE | ID: mdl-32286687
11.
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Lancet
; 394(10215): 2155-2164, 2019 12 14.
Article
in English
| MEDLINE | ID: mdl-31813636
12.
Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.
Clin Gastroenterol Hepatol
; 18(12): 2717-2723.e3, 2020 11.
Article
in English
| MEDLINE | ID: mdl-31811950
13.
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Lancet Oncol
; 20(3): 361-370, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30709633
14.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(1): 88-99, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30509771
15.
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 21(1): 133, 2019 12 03.
Article
in English
| MEDLINE | ID: mdl-31796073
16.
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
N Engl J Med
; 374(3): 211-22, 2016 Jan 21.
Article
in English
| MEDLINE | ID: mdl-26789870
17.
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Breast Cancer Res Treat
; 178(2): 389-399, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31428908
18.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 497-509, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29501363
19.
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.
Pharmacogenet Genomics
; 28(6): 147-152, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29768301
20.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Breast Cancer Res Treat
; 168(1): 69-77, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29128898